AMD is the leading cause of blindness in people over 50 years of age. It is caused by the breakdown of the central portion of the retina (the nerve layer part of your eye that works like the film in a camera to pick up the picture) called the macula. the macula is responsible for the fine central vision in the eye that is needed for driving a car, reading fine print, recognizing faces, etc.
There are two types of macular degeneration: dry (non-neovascular) and wet (neovascular). In the "wet" form of AMD, abnormal blood vessels grow in the back of the eye. Sometimes these vessels leak blood or fluid that causes blurred and distorted vision. This process is also known as choroidal neovascularizaion (CNV). For people affected by "wet" AMD, vision loss may be quick and severe. This study is for participants with "wet" AMD.
The purpose of this study is to evaluate the effects of investigational drug in research participants with wet AMD, and how it is absorbed into the body, when administered in combination with other AMD drugs. An investigational drug is one which has not been approved by the U.S. Food and Drug Administration (FDA) but is available in research studies like this one.
Spectri Clinical Trial
Omaspect Extension Clinical Trial
We are conducting a clinical trial to evaluate a drug called lampalizumab for patients with geographic atrophy (GA), a form of dry age-related macular degeneration (AMD).
GA causes progressive damage to the macula, the central region of the retina (inside the eye), which is involved in seeing the fine details associated with reading, driving, and recognizing faces. In the advanced stage of the disease, GA results in severe central vision loss, which impairs performance of many activities of daily living.
The cause of AMD is not well understood. However, recent scientific studies have found that people with specific inherited (genetic) characteristics have an increased risk of AMD. Other scientific studies also suggest that an increased activation of a specific part of your immune system called the "alternative completment pathway" may be involved in the disease. Currently, there is no approved treatment for GA. Lampalizumab, the study drug, is designed to slow down the activation of the alternative complement pathway and is given by injection into the eye.
The purpose of this study is to compare the effects, good or bad, of lampalizumab versus sham (false) injection and also to see if lampalizumab works differently in people with specific inherited (genetic) characteristics with an increased risk of AMD. In this study, participants will get either lampalizumab or sham injection.
FOR MORE INFORMATION: